AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32320078
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (CO2 laser treatment followed by three courses of oral traditional Chinese medicine)
Trial: 32320078
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CO2 laser treatment only)
Trial: 32320078
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy group
Trial: 35908167
Drug: Dexamethasone 24
RxNorm normalized name: dexAMETHasone 24 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 24 mg
Trial: 33030703
Drug: Vericiguat 15
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vericiguat 15 mg (single dose)
Trial: 33030703
Drug: Vericiguat 10
RxNorm normalized name: vericiguat 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vericiguat 10 mg (once daily)
Trial: 33030703
Drug: Vericiguat 2.5
RxNorm normalized name: vericiguat 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vericiguat 2.5 mg (single or multiple doses)
Trial: 34973039
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure (PE) plus pill placebo (PE+PLB)
Trial: 34973039
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure (PE) plus sertraline (PE+SERT)
Trial: 32537238
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care smoking cessation treatment (counseling and nicotine replacement therapy)
Trial: 32369032
Drug: Prostate Cancer
RxNorm normalized name: Leuprolide Acetate 22.5mg Lyophilisate for suspension for injection [Prostate Cancer] with Diluent, Transfer Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate Cancer Screening Preparation (PCSPrep)
Trial: 35090887
Drug: Electrical dry
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrical dry needling plus corticosteroid injection (electrical-DN+CSI)
Trial: 34557956
Drug: PBM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBM therapy
Trial: 35458131
Drug: Multi-Ingredient Supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-Ingredient Supplement (MS)
Trial: 33537776
Drug: Lipopolysaccharide (LPS)
RxNorm normalized name: sulfated mucopolysaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipopolysaccharide (LPS) treatment (2.0 ng/kg)
Trial: 34472596
Drug: aboBoNT‐A solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aboBoNT‐A solution 50 U
Trial: 35237893
Drug: Astaxanthin (AST)
DrugBank: Astaxanthin (DB06543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin (AST) 8 mg daily for 40 days
Trial: 34529963
Drug: MenACWY (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY (first dose) followed by placebo (second dose)
Trial: 35501178
Drug: NVX-CoV2373 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVX-CoV2373 (5 μg SARS-CoV-2 rS; 50 μg Matrix-M1)
Trial: 33164276
Drug: Emricasan (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emricasan (25 mg twice daily for 24 months)
Trial: 33164276
Drug: Emricasan (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emricasan (25 mg twice daily for 24 months) in F3 to F5 subgroup
Trial: 32191001
Drug: Low intensity-shockwave
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity-shockwave therapy (Li-ESWT), 6 sessions over three weeks
Trial: 34899419
Drug: Gamified AACTP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamified AACTP smartphone application + treatment as usual (TAU)
Trial: 32894140
Drug: Isocaloric carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric carbohydrate supplements (CHO)
Trial: 33037200
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid withdrawal
Trial: 33307024
Drug: Sequential group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential group (invitation to primary colonoscopy and invitation for FIT for initial nonresponders)
Trial: 34033935
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with 150 µM methylene blue for 2 minutes and a 660 nm wavelength laser for 3 minutes (100 mW, 600 J/cm², total 18J)
Trial: 35878732
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g resistant starch (RS) daily
Trial: 35468601
Drug: Brolucizumab 3
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brolucizumab 3 mg
Trial: 33775019
Drug: Massage with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage with sunflower oil (emollient therapy)
Trial: 35934913
Drug: Hydroxyurea (1–2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (1–2 g d1–5) with cytarabine (1 g/m2/2 h b.i.d. d1–5) and daunorubicin (60 mg/m2 d1–3)
Trial: 35934913
Drug: Hydroxyurea (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (1 g)
Trial: 35934913
Drug: Ex vivo
RxNorm normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex vivo drug sensitivity assays
Trial: 35934913
Drug: Hydroxyurea with
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea with standard chemotherapy
Trial: 35867022
Drug: Octreotide infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide infusion for 3 days after transplant
Trial: 32351591
Drug: 8-week moderate-intensity
RxNorm normalized name: Rheumatrex Dose Pack 8, 4 Week Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week moderate-intensity continuous aerobic exercise program with standard medical treatment
Trial: 32351591
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment without any exercise program
Trial: 36142070
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa seeds (3 capsules daily, 2 in the morning and 1 in the evening)
Trial: 36142070
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa seeds (3 capsules every 12 hours)
Trial: 36142070
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa seeds (5 capsules in the morning and 4 in the evening)
Trial: 36142070
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa powder (1 capsule every 12 hours)
Trial: 36142070
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa powder (2 capsules every 12 hours)
Trial: 36142070
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa powder (3 capsules every 12 hours)
Trial: 36142070
Drug: Charcoal capsules
RxNorm normalized name: charcoal Oral Capsule
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Charcoal capsules (control group)
Trial: 33527863
Drug: Base ointment
RxNorm normalized name: Unibase Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Base ointment (Eucerin) for daily wound dressing
Trial: 34110925
Drug: Involved field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved field radiation therapy (IFRT)
Trial: 34110925
Drug: Posterior fossa
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior fossa radiation therapy (PFRT)
Trial: 34110925
Drug: Low-dose craniospinal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose craniospinal irradiation (LDCSI; 18 Gy)
Trial: 34110925
Drug: Standard-dose craniospinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose craniospinal irradiation (SDCSI; 23.4 Gy)
Trial: 34110925
Drug: Involved field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved field radiation therapy (IFRT) in Sonic Hedgehog MB
Trial: 34110925
Drug: Low-dose craniospinal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose craniospinal irradiation (LDCSI) in group 4 MB
Trial: 34110925
Drug: Standard-dose craniospinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose craniospinal irradiation (SDCSI)
Trial: 34528122
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg bolus, 1 mg/kg infusion for first 30 min, followed by 0.5 mg/kg infusion for further 30 min)
Trial: 34528122
Drug: NSAIDs (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (50 mg dexketoprofen trometamol and saline)
Trial: 32385815
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid (CA) treatment (5 mM) under Ni stress
Trial: 32385815
Drug: Nickel (Ni)
DrugBank: Nickel sulfate (DB14180)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nickel (Ni) treatment alone
Trial: 32385815
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid (CA) treatment under Ni stress
Trial: 33025652
Drug: Potassium-sparing diuretics
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium-sparing diuretics and aldosterone antagonists
Trial: 33025652
Drug: Vasodilator antihypertensives
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasodilator antihypertensives
Trial: 32985036
Drug: Standard manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard manual therapy (MT)
Trial: 610148118
Drug: Modern diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern diet (9217.6 kJ, macronutrient composition 331.7:66.1:76.9 g)
Trial: 610148118
Drug: Traditional diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional diet (8807.3 kJ, macronutrient composition 364.3:30.1:66.4 g)
Trial: 32181499
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of treatment (regression subgroup)
Trial: 34225066
Drug: AIs alone
RxNorm normalized name: AI-128
DrugBank: AI-128 (DB05841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIs alone (AI monotherapy)
Trial: 33610954
Drug: Mandibular Advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular Advancement Splint (MAS) therapy
Trial: 33290937
Drug: Cat adoption
RxNorm normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cat adoption (treatment group)
Trial: 36291165
Drug: Intramuscular hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular hypertonic saline solution (6%)
Trial: 36291165
Drug: Intramuscular isotonic
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular isotonic saline solution (0.9%)
Trial: 33079393
Drug: Education plus
RxNorm normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education plus exercise and physical therapy (LEAP)
Trial: 33079393
Drug: Underwent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Underwent chemotherapy
Trial: 33410616
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg twice daily)
Trial: 33410616
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg once daily)
Trial: 36282186
Drug: Alirocumab (15–100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (15–100 mg)
Trial: 36282186
Drug: Evolocumab (21–140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (21–140 mg)
Trial: 34413142
Drug: Hyoscine N-butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine N-butylbromide (20 mg IV)
Trial: 34413142
Drug: Loperamide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (4 mg orally)
Trial: 33821363
Drug: weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: weekly paclitaxel plus cetuximab (wPTX-Cmab)
Trial: 34799380
Drug: Olaparib (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (2 years of maintenance therapy)
Trial: 33710371
Drug: Ultra-low-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose CT (ULD-CT) with tin filtration (Sn140kV/50mAs)
Trial: 33710371
Drug: Ultra-low-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose CT (ULD-CT)
Trial: 33710371
Drug: Ultra-low-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose CT (ULD-CT) and Standard CT
Trial: 32547310
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg orally for six months
Trial: 33066812
Drug: Online cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online cognitive behavioral therapy for insomnia (6 online sessions weekly + 2 face-to-face sessions)
Trial: 33399016
Drug: Drug Adjustment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Adjustment (DA)
Trial: 34890827
Drug: Peanut Oral
RxNorm normalized name: Peanut Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut Oral Immunotherapy (POIT) with a daily maintenance dose of 3,900 mg
Trial: 34890827
Drug: Peanut Oral
RxNorm normalized name: Peanut Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut Oral Immunotherapy (POIT) during maintenance
Trial: 34890827
Drug: Peanut Oral
RxNorm normalized name: Peanut Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut Oral Immunotherapy (POIT) after 1-month treatment discontinuation
Trial: 34890827
Drug: Biomarker analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker analysis after 1-month discontinuation
Trial: 35879013
Drug: App-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App-based treatment
Trial: 34967805
Drug: Preincision local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preincision local anesthetic injection
Trial: 34967805
Drug: Postprocedure local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprocedure local anesthetic injection
Trial: 32756520
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (morphine as primary analgesic)
Trial: 34274044
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate 25 mg/day
Trial: 34349841
Drug: Oral vinorelbine-cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vinorelbine-cisplatin (OV-CDDP) - 60–80 mg/m2 OV days 1 and 8 with 80 mg/m2 CDDP day 1
Trial: 34349841
Drug: Gemcitabine-cisplatin (GEM-CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemcitabine-cisplatin (GEM-CDDP) - 1250 mg/m2 GEM days 1 and 8 with 75 mg/m2 CDDP day 1
Trial: 35384398
Drug: 200-mg generic
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200-mg generic pazopanib tablet
Trial: 35384398
Drug: 200-mg branded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-mg branded pazopanib tablet
Trial: 32930848
Drug: 320 mg
RxNorm normalized name: aspirin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg anthocyanins daily for 12 weeks
Trial: 33023671
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma infusion (two bags of 238-337 ml each on day 1 and day 2)
Trial: 33023671
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma infusion
Trial: 32729819
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of memantine 10-mg tablet under fasting condition
Trial: 32729819
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of memantine 10-mg tablet under fed condition
Trial: 32729819
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (Ebixa 10-mg tablet)
Trial: 36181632
Drug: VOM ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VOM ethanol infusion
Trial: 33704435
Drug: Vaccinated patients
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated patients (received at least one dose of mRNA COVID-19 vaccine)
Trial: 33704435
Drug: Unvaccinated patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unvaccinated patients (did not receive vaccine)
Trial: 33704435
Drug: Vaccinated patients
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated patients >10 days after 1st dose
Trial: 33704435
Drug: Vaccinated patients
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated patients >0 days after 2nd dose
Trial: 33205064
Drug: AKR-001 (Fc-FGF21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKR-001 (Fc-FGF21 fusion protein) at 70 mg QW
Trial: 34391872
Drug: Metformin (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (maximum dose 2,000 mg/d)
Trial: 34376438
Drug: Transmuscular quadratus
RxNorm normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmuscular quadratus lumborum (TQL) block with 0.375% ropivacaine 20 mL on each side
Trial: 34376438
Drug: Oblique subcostal
RxNorm normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oblique subcostal transversus abdominis plane (OSTAP) block with 0.375% ropivacaine 20 mL on each side
Trial: 34853883
Drug: Maternal bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal bone resorption (measured by urinary excretion of cross-linked N-telopeptides) during pregnancy
Trial: 35531319
Drug: Intravenous analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous analgesia with tramadol
Trial: 35531319
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Intravenous analgesia with sufentanil)
Trial: 35869955
Drug: Controlled-release dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Controlled-release dinoprostone vaginal insert
Trial: 34562728
Drug: Cognitive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive training plus treatment as usual
Trial: 34580638
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine vs Placebo
Trial: 34580638
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine vs Exenatide
Trial: 35018648
Drug: Propofol target-controlled
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target-controlled infusion (TCI) with effect compartment concentration set to 3 μg/ml
Trial: 34189335
Drug: Active deep
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active deep brain stimulation (DBS) targeting the ventral capsule/ventral striatum (VC/VS) region for three months
Trial: 32342831
Drug: Dabigatran treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran treatment